Chiglitazar vs Lanifibranor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: PPAR (pan-agonist) · full Type 2 Diabetes pipeline

Chiglitazar · Bilessglu

Marketed by Chipscreen Biosciences

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT02173457 · Phase 3 · completed

In this randomized, double-blind, active-controlled Phase 3 trial, 740 patients with type 2 diabetes were randomized to chiglitazar (32mg or 48mg) or sitagliptin. At 24 weeks, chiglitazar met its non-inferiority margin against sitagliptin on HbA1c reduction, with very small treatment differences of -0.04 and -0.08 percentage points.

Next expected readout: December 2030 · NCT07303803 (registry estimate)

Reported efficacy

percentage of HbA1c change from baseline (24 weeks): RECAM study, n=533 (178/177/178). LS mean change in HbA1c from baseline at Week 24: -0.91% (32mg), -1.14% (48mg), -0.49% (placebo); both doses vs placebo p<0.001; 48mg vs 32mg p=0.008. (met)

Result source: NCT04807348

Lanifibranor

Developed by Inventiva and partners

Phase 2 in Type 2 Diabetessmall molecule
Partial signal

NCT05232071 · Phase 2 · completed

This trial was randomized, blinded, and placebo-controlled, and its posted results showed lanifibranor and lanifibranor-plus-empagliflozin both significantly lowered HbA1c versus placebo at 24 weeks. However, the trial enrolled only 39 patients across three arms, explicitly designed as an early proof-of-concept study, which is too small to serve as strong, confirmatory evidence on its own.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Assessment of the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24 (Date of randomisation until the end of treatment at week 24): HbA1c absolute change from baseline to Week 24: lanifibranor (800mg) -1.14% and lanifibranor+empagliflozin -1.59%, vs +0.26% increase on placebo; the study achieved the primary efficacy endpoint (met)

Result source: NCT05232071

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointChiglitazarLanifibranor
HbA1c, change-1.1% vs -0.5%a−0.6 vs placebo48mg · wk 24NCT04807348
1 other result
  • -0.9% vs -0.5% 32mg · wk 24 · Phase 3 · primary NCT04807348
-0.7% vs -0.1%−0.6 vs placebowk 24 · n 20NCT03459079
2 other results
  • -1.1% vs 0.3% lanifibranor (800mg) · wk 24 · Phase 2 · primary NCT05232071
  • -1.6% vs 0.3% wk 24 · Phase 2 · primary NCT05232071
Body weight, change (kg)—Not posted · NCT02173457—Not reported
HbA1c below 7%—Not posted · NCT02173457—Not reported
Fasting plasma glucose, change—Not posted · NCT02173457—Not reported
3-point MACE (% with event)—Not posted · NCT02173457—Not reported

HbA1c, change

Chiglitazar
-1.1% vs -0.5%a−0.6 vs placebo48mg · wk 24NCT04807348
1 other result
  • -0.9% vs -0.5% 32mg · wk 24 · Phase 3 · primary NCT04807348
Lanifibranor
-0.7% vs -0.1%−0.6 vs placebowk 24 · n 20NCT03459079
2 other results
  • -1.1% vs 0.3% lanifibranor (800mg) · wk 24 · Phase 2 · primary NCT05232071
  • -1.6% vs 0.3% wk 24 · Phase 2 · primary NCT05232071

Body weight, change (kg)

Chiglitazar
—Not posted · NCT02173457
Lanifibranor
—Not reported

HbA1c below 7%

Chiglitazar
—Not posted · NCT02173457
Lanifibranor
—Not reported

Fasting plasma glucose, change

Chiglitazar
—Not posted · NCT02173457
Lanifibranor
—Not reported

3-point MACE (% with event)

Chiglitazar
—Not posted · NCT02173457
Lanifibranor
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Chiglitazar: 0 of 4 rows · Lanifibranor: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricChiglitazarLanifibranor
Dropout rate—
30%a
NCT03459079 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs—
20%a
NCT03459079 · Phase 2 · registry result, not featured evidence
Serious AEs—
5%a
NCT03459079 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs—
a
diarrhoea 26.3% (placebo 16.7%)
elevated lipase level 25% (placebo 16.7%)
anaemia 20% (placebo 11.1%)
NCT03459079 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Chiglitazar

HbA1c -0.08% @ 24wkchiglitazar 48mg
absolute change · percentage points
No placebo or comparator arm
NCT02173457 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-0.04% @ 24wkchiglitazar 32mg
NCT02173457 · Phase 3 · sponsor-reported, not registry data

Lanifibranor

Hepatic Fat Fraction -8.7% (n=20) vs -3% (n=18) placebo @ 24wk
percent change · % of baseline
NCT03459079 · Phase 2 · registry result, not featured evidence
Hepatic Fat Fraction 30% Reduction 65% (n=20) vs 22% (n=18) placebo @ 24wk
responder rate · % of participants
NCT03459079 · Phase 2 · registry result, not featured evidence
NAFLD Resolution 25% (n=20) vs 0% (n=18) placebo @ 24wk
responder rate · % of participants
NCT03459079 · Phase 2 · registry result, not featured evidence
HOMA-IR -26% (n=20) vs -7% (n=18) placebo @ 24wk
percent change · % of baseline
NCT03459079 · Phase 2 · registry result, not featured evidence
HDL-C Change mg/dL 7.6 vs 0.9 placebo mg/dL @ 24wk
absolute change · mg/dL
NCT03459079 · Phase 2 · registry result, not featured evidence
Liver Stiffness FibroScan Change kPa -1.49 vs -0.34 placebo absolute change in kPa from baseline @ 24wk
absolute change · absolute change in kPa from baseline
NCT03459079 · Phase 2 · registry result, not featured evidence
Liver Stiffness MRE Change kPa 0.23 vs -0.06 placebo kPa @ 24wk
absolute change · kPa
NCT03459079 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Chiglitazar's landscape · Lanifibranor's landscape